Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 79,351 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Healthy
Interventions: Ixekizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Daytona Beach, Florida • Miami, Florida • Dallas, Texas + 1 more

Conditions: Mandibular Reconstruction, Segmental Mandibular Defects
Interventions: Surgical Resection and Reconstruction; Procedure
Lead sponsor: AO Innovation Translation Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: 2022 – 2030
U.S. locations: 5
States / cities: Jacksonville, Florida • Chicago, Illinois • New Hyde Park, New York + 2 more

Conditions: Stroke
Interventions: transcranial random noise stimulation and functional electrical stimulation facilitated task practice; Device
Lead sponsor: Amit Sethi; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: IDH1-Mutated Malignancies
Interventions: Ivosidenib Oral Tablet; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Columbus, Ohio • Houston, Texas

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Imeroprubart, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 33
States / cities: Tucson, Arizona • Carlsbad, California • Mission Hills, California + 28 more

Conditions: Aging
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
Interventions: Biological/Vaccine: Bacillus Calmette-Guerin (BCG); Biological
Lead sponsor: Steven E Arnold, MD; Other
Eligibility: 55 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Neoplasms
Interventions: TAS-114/capecitabine; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Indianapolis, Indiana • Detroit, Michigan

Conditions: Hepatic Impairment
Interventions: Aramchol free acid tablet 600mg, single dose, Aramchol free acid tablet 300mg, bid; Drug
Lead sponsor: Galmed Research and Development, Ltd.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Conditions: Cardiac Arrest
Interventions: Packed Red Blood Cells (1 unit), Packed Red Blood Cells (2 units), Saline; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronavirus Infection
Interventions: Hydroxychloroquine Sulfate, Azithromycin, Chloroquine Sulfate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Hypertension
Interventions: Cardene® I.V.; Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: 2 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Beverly Hills, California • Miami, Florida

Conditions: ALS
Interventions: Respiratory Muscle Training; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Transplant; Failure, Kidney
Interventions: Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids; Drug
Lead sponsor: Gaetano Ciancio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Solid Tumors, Metastatic Melanoma
Interventions: losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Salt Lake City, Utah

Conditions: Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
Interventions: Brimonidine Tartrate, Placebos; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more

Conditions: Diabetes Mellitus in Pregnancy
Interventions: SweetMama Focus Groups, SweetMama Individual Testing, SweetMama Feasibility Testing - Pilot Randomized Trial; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fecal Incontinence
Interventions: Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study, control group; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Sepulveda, California

Conditions: Metastatic Breast Cancer
Interventions: Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 27
States / cities: Sedona, Arizona • Tucson, Arizona • San Francisco, California + 22 more

Conditions: Advanced Solid Tumor
Interventions: Entrectinib, Midazolam Hydrochloride; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee

Conditions: HIV I Infection
Interventions: Estradiol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Interventions: Paclitaxel protein bound, Gemcitabine, Cisplatin, Hydroxychloroquine; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Low Back Pain, Chronic Pain
Interventions: Physical Therapy, Cognitive Behavioral Therapy, Mindfulness, Phase I Treatment, Phase II Switching; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 64 Years
Enrollment: 749 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Baltimore, Maryland • Salt Lake City, Utah

Search by objective public record fields.

A Study of Two Formulations of Ixekizumab in Healthy Participants

Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

t-RNS After Hand Recovery in Chronic Stroke

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The South Texas Aging Registry and Repository

A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD

A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Packed Red Blood Cell Transfusion During Cardiac Arrest

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

Respiratory Muscle Training (RMT) in ALS

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women

Treatment of Patients With Fecal Incontinence

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer

Optimize Low Back Pain